About Menactra Vaccine"About Menactra Vaccine" header

Menactra vaccine booster dose has proven immunogenicity

  • >99% of trial participants achieved protective antibody levels (SBA-Ha titers ≥1:8)1
  • ≥95% of trial participants achieved a ≥4-fold rise in SBA-H titer1
  • Menactra vaccine provides protection against invasive meningococcal disease from 4 vaccine-preventable serogroups (A, C, Y, and W-135)1

    Five serogroups, A, B, C, Y, and W-135, are responsible for almost all cases of meningococcal disease worldwide2

  • Menactra vaccine booster injection was shown to be safe1

    The most common solicited injection site and systemic reactions within 7 days after booster vaccination were pain and myalgia. Other adverse reactions may occur.

    Overall rates of solicited injection site reactions and solicited systemic reactions were similar to those observed in adolescents and adults receiving a primary dose of Menactra vaccine in previous studies.

Image of teenage boy with graphic t-shirt

A robust immune response in adolescents after the primary dose1

  • The immunogenicity of Menactra vaccine has been proven in clinical trials — and confirmed in everyday use
  • Adolescents achieved robust immune responses after receiving a primary dose

Menactra vaccine has a long-established record of safety

Over 78 million doses of Menactra vaccine have been distributed,3 and more than 52,000 infants, children, adolescents, and adults have been included in 29 clinical trials.4-6

Approved for infants as young as 9 months of age in 2011 
Approved for individuals 2-10 years of age in 2007 
Approved for individuals 11-55 years of age in 2005 
Approved for one-time booster vaccination in individuals 15-55 years of age in 2014 

aSBA-H = serum bactericidal assay using human complement.

Ordering Menactra vaccine at VaccineShoppe.com is easy.
Go Now


Menactra vaccine is contraindicated in persons with a known hypersensitivity (eg, anaphylaxis) to any component of the vaccine.

Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks.

Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions.

The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur. Vaccination with Menactra vaccine may not protect all individuals.


Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Before administering Menactra vaccine, please see accompanying full Prescribing Information.